Recurrence and occurrence of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment for chronic hepatitis C in patients with advanced liver disease: Turkish multicenter early access program

2018 ◽  
Vol 68 ◽  
pp. S301-S302
Author(s):  
R. Jdilman ◽  
M. Demir ◽  
M. Aladag ◽  
S. Kaymakoglu ◽  
C. Erol ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Advanced Liver Disease ◽  
Early Access ◽  
Access Program

scholarly journals Advanced liver disease in Russian children and adolescents with chronic hepatitis C

2019 ◽  
Vol 26 (7) ◽  
pp. 881-892 ◽  
Author(s):  
Anna Turkova ◽  
Galina V. Volynets ◽  
Siobhan Crichton ◽  
Tamara A. Skvortsova ◽  
Victoria N. Panfilova ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Children And Adolescents ◽  
Chronic Hepatitis C ◽  
Advanced Liver Disease

A Review on the Use of Eltrombopag in Patients with Advanced Liver Disease

2009 ◽  
Vol 1 ◽  
pp. CMT.S2267
Author(s):  
Edoardo G. Giannini ◽  
Alfredo Greco ◽  
Vincenzo Savarino
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Antiviral Treatment ◽  
Pegylated Interferon ◽  
Severe Thrombocytopenia ◽  
Current Standard ◽  
Advanced Liver Disease ◽  
Orally Bioavailable

Thrombocytopenia is the most common hematological abnormality in patients with chronic, advanced liver disease. In these patients, the presence of severe thrombocytopenia is an obstacle to the performance of invasive diagnostic and therapeutic procedures, and the current standard treatment for these patients is platelet transfusions, a remedy whose characteristics are far from being ideal. Furthermore, thrombocytopenia in patients with chronic hepatitis C virus infection may render the patients ineligible to antiviral treatment or may limit its efficacy because of premature discontinuation. Although the cause of thrombocytopenia in patients with chronic liver disease is likely multi-factorial, decreased thrombopoietin production by the liver undoubtedly plays a significant role. In this regard, eltrombopag, a non-peptide, orally bioavailable thrombopoietin receptor agonist has been shown to safely increase platelet count in a dose-dependent fashion in both healthy subjects and thrombocytopenic patients with chronic hepatitis C. Furthermore, in this latter group of patients, it has been shown to be superior to placebo in counteracting the myelosuppressive effect of short-term pegylated interferon treatment.

SVR reduces ethnic disparities in progression to advanced liver disease in patients with chronic hepatitis C

2017 ◽  
Vol 66 (1) ◽  
pp. S283-S284
Author(s):  
A.K. Le ◽  
C. Zhao ◽  
J. Hoang ◽  
L.A. Yasukawa ◽  
J. Zhang ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Ethnic Disparities ◽  
Advanced Liver Disease

Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients

2017 ◽  
Vol 206 (2) ◽  
pp. 165-174 ◽  
Author(s):  
Abdolvahab Alborzi ◽  
Tayebeh Hashempour ◽  
Javad Moayedi ◽  
Zahra Musavi ◽  
Gholamreza Pouladfar ◽  
...  
Keyword(s):  
Genetic Variation ◽  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Serum Level ◽  
Chronic Hepatitis C ◽  
Advanced Liver Disease ◽  
Chronic Hepatitis C Patients
Sign in / Sign up

Export Citation Format

Share Document